Gemtuzumab
Mylotarg (gemtuzumab) is an antibody pharmaceutical. Gemtuzumab was first approved as Mylotarg on 2018-04-19. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against myeloid cell surface antigen CD33.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mylotarg | Biologic Licensing Application | 2021-09-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9203 | Injection, gemtuzumab ozogamicin, 0.1 mg |
Clinical
Clinical Trials
98 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Promyelocytic leukemia acute | D015473 | C92.4 | — | 4 | — | — | 1 | 5 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 3 | — | — | — | 3 | |
| Megakaryoblastic leukemia acute | D007947 | C94.2 | 1 | 3 | — | — | — | 3 | |
| Monocytic leukemia acute | D007948 | 1 | 3 | — | — | — | 3 | ||
| Myelomonocytic leukemia acute | D015479 | C92.5 | 1 | 3 | — | — | — | 3 | |
| Myeloid leukemia | D007951 | C92 | 2 | 3 | — | — | — | 3 | |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 1 | 3 | — | — | — | 3 |
| Philadelphia chromosome | D010677 | — | 1 | — | — | — | 1 | ||
| Myeloid sarcoma | D023981 | C92.3 | — | 1 | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GEMTUZUMAB |
| INN | gemtuzumab |
| Description | Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 220578-59-6 |
| RxCUI | 1294580 |
| ChEMBL ID | CHEMBL2108342 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00056 |
| UNII ID | 93NS566KF7 (ChemIDplus, GSRS) |
Target
Agency Approved
CD33
CD33
Organism
Homo sapiens
Gene name
CD33
Gene synonyms
SIGLEC3
NCBI Gene ID
Protein name
myeloid cell surface antigen CD33
Protein synonyms
CD33, CD33 antigen (gp67), CD33 molecule transcript, gp67, Sialic acid-binding Ig-like lectin 3, Siglec-3
Uniprot ID
Mouse ortholog
Cd33 (12489)
myeloid cell surface antigen CD33 (Q63997)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,632 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mylotarg
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,103 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more